Wednesday morning news drop
Why You Should Be Wary of Wall Street’s Upbeat Stock Forecasts Amid rising inflation and the threat of recession, corporate earnings are coming under pressure. (New York Times)
A Giant Distraction to the Business of Investing: The average drawdown of the top 10 stocks from last fall is a decline of 30.1%. This compares rather unfavorably with the drawdown in the S&P 500 of -17.4%. Only two stocks have a drawdown that beats the S&P 500 — Apple and Visa. Eight out of the top 10 are down more than the market itself. Many of these stocks are down in a big way. (A Wealth of Common Sense)
Loans Could Burn Start-Up Workers in Downturn Tech workers took out loans based on the value of their start-up stock in recent years. That may come back to haunt them. (New York Times)
The future of remote work, according to 6 experts Make the case for working remotely — but not so much that your job gets outsourced. (Vox)
Incognito Mode Isn’t As Incognito As You Might Think: Private browsing (aka incognito mode) is a great way to prevent your web browser from saving what you do. But to call it privacy-focused is a stretch, and while your browser or device doesn’t log your movements in its history and cookies, that doesn’t mean the sites you visit don’t clock your behavior. Despite its name, you’re not really incognito, and you may want to dial back your confidence in what these modes really do. (Wirecutter)
New COVID Vaccines Will Be Ready This Fall. America Won’t Be. Respiratory-virus season starts soon, and our autumn vaccine strategy is shaky at best. (The Atlantic)
The Three Pillars of Happiness Being happy isn’t just about getting the details right. Here are some truths that transcend circumstance and time. (The Atlantic)
Can Pickleball Save America? The sport, beloved for its democratic spirit, could unite the country—if it doesn’t divide itself first. (New Yorker)
The High-Stakes Race to Engineer New Psychedelic Drugs As psychedelic therapies for mental health go mainstream, companies are recruiting chemists to create patentable versions of hallucinogens. Critics say it’s all a bad trip. (Wired)